China Nuokang Bio-Pharma Falls on NY Debut
By wchung | 25 Mar, 2026
Shares of China Nuokang Bio-Pharmaceutical Inc. fell nearly 4 percent in their trading debut Thursday after pricing at $9 per American depositary share, below their expected range.
The China-based biopharmaceutical company, which specializes in blood and cardiovascular treatments, had expected the initial public offering of 5 million ADSs to price between $10 and $12.
The company said net proceeds from the offering totaled about $32.9 million. The company plans to use the funds to grow its sales and marketing platform, for new acquisitions, for research and to expand manufacturing facilities.
Shares, which trade under the symbol “NKBP” on the Nasdaq, fell 33 cents, or 3.7 percent, to close at $8.67 with about 2.3 million shares changing hands during the session.
12/10/2009 4:53 PM NEW YORK (AP)
Articles
- SK Hynix Files for US Listing to Raise Up to $14 Billion
- NASA to Spend $20 Billion on Moon Base, Cancel Lunar Orbit Station
- Humphrey Yang Simplifies Wealth Building for the TikTok Generation
- Pakistan Offers to Host Actual Peace Talks—IRL
- Mandopop Legend Jay Chou to Release First Album in 4 Years
- Japan's Cherry Blossom Picnics Pinched by 25% Food Inflation Since 2020
- SK Hynix Places Record $8 Billion Order for ASML EUV Lithography Tools
- TSMC Capacity a Major Bottleneck for AI Buildout Says Broadcom
- BTS Army to Bring $5.3 Billion Spending Power to a City Near You
- Zoox to Expand Robotaxi Service into San Francisco and Las Vegas